4.6 Article

Prognostic Impact of Race in Patients Undergoing PCI Analysis From 10 Randomized Coronary Stent Trials

期刊

JACC-CARDIOVASCULAR INTERVENTIONS
卷 13, 期 13, 页码 1586-1595

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2020.04.020

关键词

prognosis; race; stent

资金

  1. Abbott
  2. Abbott Vascular
  3. Terumo
  4. St. Jude Medical
  5. Biotronik
  6. Boston Scientific
  7. Medtronic
  8. NIH/NHLBI [T32 HL007854]
  9. Abbott Laboratories
  10. AstraZeneca
  11. Bayer
  12. Beth Israel Deaconess
  13. Bristol-Myers Squibb
  14. CERC
  15. Chiesi
  16. Concept Medical
  17. CSL Behring
  18. DSI
  19. Novartis Pharmaceuticals
  20. OrbusNeich
  21. Spectranetics/Philips/Volcano Corp

向作者/读者索取更多资源

OBJECTIVES The aim of this study was to assess race-based differences in patients undergoing percutaneous coronary intervention from a large pooled database of randomized controlled trials. BACKGROUND Data on race-based outcomes after percutaneous coronary intervention are limited, deriving mainly from registries and single-center studies. METHODS Baseline characteristics and outcomes at 30 days, 1 year, and 5 years were assessed across different races, from an individual patient data pooled analysis from 10 randomized trials. Endpoints of interest included death, myocardial infarction, and major adverse cardiac events (defined as cardiac death, myocardial infarction, or ischemia-driven target lesion revascularization). Multivariate Cox proportional hazards regression was performed to assess associations between race and outcomes, controlling for differences in 12 baseline covariates. RESULTS Among 22,638 patients, 20,585 (90.9%) were white, 918 (4.1%) were black, 404 (1.8%) were Asian, and 473 (2.1%) were Hispanic. Baseline and angiographic characteristics differed among groups. Five-year major adverse cardiac event rates were 18.8% in white patients (reference group), compared with 23.9% in black patients (p = 0.0009), 11.2% in Asian patients (p = 0.0007), and 21.5% in Hispanic patients (p = 0.07). Multivariate analysis demonstrated an independent association between black race and 5-year risk for major adverse cardiac events (hazard ratio: 1.28; 95% confidence interval: 1.05 to 1.57; p = 0.01). CONCLUSIONS In the present large-scale individual patient data pooled analysis, comorbidities were significantly more frequent in minority-group patients than in white patients enrolled in coronary stent randomized controlled trials. After accounting for these differences, black race was an independent predictor of worse outcomes, whereas Hispanic ethnicity and Asian race were not. Further research examining race-based outcomes after percutaneous coronary intervention is warranted to understand these differences. (c) 2020 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据